Relation between Changes in Cellular Load, Evolution of Viral Phenotype, and the Clonal Composition of Virus Populations in the Course of Human Immunodeficiency Virus Type 1 Infection
about
sameAs
HIV-1 induced bystander apoptosisClinical significance of HIV-1 coreceptor usage.Bioinformatic analysis of HIV-1 entry and pathogenesis.HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells.Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy.Evolutionary dynamics of HIV-induced subversion of the immune response.Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmiEvolution of syncytium-inducing and non-syncytium-inducing biological virus clones in relation to replication kinetics during the course of human immunodeficiency virus type 1 infection.Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1Role of naturally occurring basic amino acid substitutions in the human immunodeficiency virus type 1 subtype E envelope V3 loop on viral coreceptor usage and cell tropismNeurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transportDetection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisNaïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy.Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.Sphingomyelin synthase 2, but not sphingomyelin synthase 1, is involved in HIV-1 envelope-mediated membrane fusion.The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppressionIn vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell declineHIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivoDifferential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1.HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activityTargeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyIncreased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loopThe host environment drives HIV-1 fitness.Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression.Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals.Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.CCL2 increases X4-tropic HIV-1 entry into resting CD4+ T cells.Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual.Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively.Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays.Viral factors in non-progression.Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.The mouse is out of the bag: insights and perspectives on HIV-1-infected humanized mouse models.High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatmentCellular tropisms and co-receptor usage of HIV-1 isolates from vertically infected children with neurological abnormalities and rapid disease progression.Coreceptor switching in HIV-1 subtype B and subtype C.Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage.
P2860
Q22241221-CFFCBA2B-10CC-4105-935E-AE70ABAD674FQ27691426-2E214F4E-53D1-4792-8E15-233A4184021DQ27693321-C0B39EFE-AC9B-4642-97D2-AEE205FF0199Q33581852-04370EBE-D292-44F7-9B57-4818A0B64357Q33636669-ED8A27AC-663A-4EC4-9461-4E122A4C0DF6Q33683341-F68D9F47-23A3-44E4-8C16-71182EB14D88Q33781934-A66F1B43-2F31-479D-AFCB-AA0261A817D4Q33784321-EA0A2830-8C80-4F4A-9D9C-60A781A86FD4Q33785473-215C2EB6-693A-46DF-8DE8-E734452ABD4BQ33815193-6A483C1D-BC3A-4EFD-8EB7-F4E445C53DF2Q33870898-ED8B7CB2-9166-40E2-B883-5F3D2E9624BCQ33951977-34D4148E-9A14-4751-8299-D8024C3B463FQ34010283-BFCFC0A1-1A1F-400D-B535-749D86978108Q34301735-3A134BF1-79E0-49F2-A286-EA025D855895Q34341001-C2A69B4B-1051-4EC7-A898-DEAAAB944120Q34431138-30F1D59A-3BA4-416F-818F-B9E1D3E9F138Q35009308-E99A08EE-AF2C-43E0-B0F9-DD1B66A027C8Q35015256-EE7A84AB-C2EA-4F4A-BF8E-695D31276C01Q35067233-5594DFE8-6EBA-4245-B0CB-B18896ACE9A2Q35127334-34768BA9-10CB-44B0-B045-47C8D4330519Q35378551-EE4CA710-0EE4-4FD8-B841-648BC560B132Q35615810-DC3E2373-9761-42F5-A417-31C60EB0D246Q35634988-E3B62E8A-8B55-4571-830E-1536FE51502EQ35893615-0E268DC7-A6D2-4A22-A518-BF26936F46F4Q36155498-667D46A0-112A-4821-8596-681D186F535DQ36225692-59DA11FF-4C34-4AAE-B7C9-B8510E94B18EQ36510410-D6DBA7D4-3064-4E91-BC92-53229CBF5CD8Q36953103-87F21F67-7033-40A8-95A6-CE3B67129FE6Q36957794-D19C3399-9358-497E-A5C9-EEE28EA3BBA0Q37059821-F4EDBEDE-7AE3-45A2-A4EB-9817535A8893Q37366730-C0EA79E6-07A8-466A-83FF-5558EB104530Q37374348-D86F8E92-EAFA-443B-A6F7-8B60A2E59D15Q37409937-9BC25457-AB21-44EE-8958-B5257E5FCCF6Q37412098-CF1878D0-9906-46EB-874F-58EF2581EE9FQ37536431-50B586A8-2521-4712-B893-4F0CE4B79096Q37900419-9489374E-9583-4785-A5D3-5C1943C0E378Q39109516-8C712A90-8587-42DF-BA6A-277A19D11D6FQ39231465-E26ABD1D-3B54-4F99-8BD2-0A1A918ADB04Q39278800-59CFF701-746D-4F5C-B4B2-5A5669794AACQ39577692-F81F6FD8-78C2-4F52-B56A-0C137767A21E
P2860
Relation between Changes in Cellular Load, Evolution of Viral Phenotype, and the Clonal Composition of Virus Populations in the Course of Human Immunodeficiency Virus Type 1 Infection
description
1996 nî lūn-bûn
@nan
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@ast
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@en
Relation between changes in ce ...... ciency virus type 1 infection.
@nl
type
label
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@ast
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@en
Relation between changes in ce ...... ciency virus type 1 infection.
@nl
altLabel
Relation between changes in ce ...... ciency virus type 1 infection.
@ast
Relation between changes in ce ...... ciency virus type 1 infection.
@en
prefLabel
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@ast
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@en
Relation between changes in ce ...... ciency virus type 1 infection.
@nl
P2093
P356
P1476
Relation between Changes in Ce ...... iciency Virus Type 1 Infection
@en
Relation between changes in ce ...... ciency virus type 1 infection.
@en
P2093
A. B. van 't Wout
H. Schuitemaker
Kootstra NA
M. Tersmette
N. A. Kootstra
R. E. Y. de Goede
Schuitemaker H
Tersmette M
P304
P356
10.1093/INFDIS/173.2.349
P407
P577
1996-02-01T00:00:00Z